Purple Biotech (PPBT) Fundamental Analysis: Revenue, Earnings & Valuation

2.97 / 10

Underperform

Fundamental rating is Underperform with a 3/10 quality score. Strengths include solid accounts‑receivable turnover and interest coverage, while fixed‑asset turnover and income‑tax‑to‑profit ratios drag performance. Overall, the fundamentals appear weak and defensive.

Analysis Checks(6/10)

Revenue-MV

Value-0.08

Score3/3

Weight49.65%

1M Return8.83%

Total operating revenue (YoY growth rate %)

Value134.75

Score2/3

Weight2.64%

1M Return0.58%

Inventory turnover ratio

Value106.57

Score3/3

Weight-2.82%

1M Return-0.67%

Accounts receivable turnover ratio

Value23.61

Score2/3

Weight-2.79%

1M Return-0.65%

PB-ROE

Value-0.98

Score1/3

Weight26.33%

1M Return5.22%

Income tax / Total profit (%)

Value22.35

Score0/3

Weight-6.34%

1M Return-1.54%

Fixed assets turnover ratio

Value9771.06

Score1/3

Weight-5.23%

1M Return-1.28%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.91

Score2/3

Weight-3.15%

1M Return-0.73%

Cost of sales ratio (%)

Value57.03

Score2/3

Weight-3.09%

1M Return-0.74%

Asset-MV

Value-0.55

Score1/3

Weight44.82%

1M Return7.28%

Is PPBT fundamentally strong?

PPBT scores 2.97/10 on fundamentals and holds a Premium valuation at present. Backed by its -123.97% ROE, 0.00% net margin, -0.14 P/E ratio, 0.39 P/B ratio, and -22.73% earnings growth, these metrics solidify its Underperform investment rating.